Diabetes

Pharmacists need support—through partnerships and reimbursement—to provide more diverse services to patients.

A study found that CT scans of visceral fat had the highest predictive performance of incident diabetes.

Health care professionals all agree that a healthy diet is the foundation of cardiovascular and cardiometabolic health, but follow-through on the population level is lacking.

These therapies are highly beneficial, but can come with a host of gastrointestinal adverse effects that patients may not be prepared to manage alone.

Some patients may have difficulty managing the gastrointestinal adverse effects associated with GLP-1 therapies.

Losing even 5% of body weight can improve comorbid conditions and other health complications for individuals with overweight and obesity.

Catch up on important diabetes news from the month of July.

From 2021 to 2022, the prevalence of adults with diabetes who used cannabis increased by 33.7%.

Patients with childhood type 1 diabetes were more likely to develop substance use disorders, mood disorders, anxiety disorders, and behavioral syndromes.

Had Novo Nordisk’s insulin icodec secured FDA approval, it would have been the first and only once-weekly basal insulin option for adults with diabetes.

Previously, data from head-to-head trials of tirzepatide and semaglutide were not available.

When used together, sodium glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) were able to lower the risk of major adverse cardiovascular events and kidney disease by 11% and 33%, respectively.

Six abstracts presented at the American Diabetes Association 84th Scientific Sessions explored how different interventions or factors can impact type 2 diabetes (T2D) management.

Individuals who ate diets that aligned closer to DASH and Mediterranean guidelines had lower levels of plasminogen activator inhibitor-1 and homocysteine biomarkers.

Three posters presented at the American Diabetes Association 84th Scientific Sessions examined GLP-1 use and cardiovascular disease risk in several different patient populations.

Three posters presented at the American Diabetes Association 84th Scientific Sessions looked into the current landscape of GLP-1s.

Two posters presented at the American Diabetes Association 84th Scientific Sessions looked into the impact of glucagon-like peptide-1 receptor agonists in type 1 diabetes management.

Test your pharmacy news knowledge with our weekly quiz.

Two posters presented at the American Diabetes Association 84th Scientific Sessions looked at challenges of remote CGM in older populations and after discharge from the hospital.

Two abstracts presented at the American Diabetes Association 84th Scientific Sessions explored how positive user experiences with a CGM can lead to better patient outcomes.

At the American Diabetes Association 84th Scientific Sessions, researchers presented findings from 4 studies that investigated the impact of various new diabetes technologies on managing the condition.